Prognostic significance of Survivin and CD44v6 in laryngeal cancer surgical margins

Survivin 和 CD44v6 在喉癌手术切缘中的预后意义

阅读:1

Abstract

OBJECTIVE: To evaluate the prognostic value of positive Survivin and CD44v6 expression in surgical margin after curative surgery for laryngeal cancer. METHODS: Immunohistochemistry was performed to detect the expression of Survivin and CD44v6 using polyclonal antibody on 112 pair of formalin-fixed, paraffin-embedded laryngeal cancer and negative surgical margin tissue samples, and results were compared with data from the prospective registry of laryngeal cancer by univariate and multivariate logistic regression model focusing specifically on recurrence. The survival was assessed by the Kaplan-Meier method and proportional hazards model. RESULTS: Survivin and CD44v6 expression in surgical margins were documented in 39.3% (n = 44) and 31.3% (n = 35) patients and were associated with a higher incidence of tumor progression and poorer disease-free survival (P < 0.01). Multivariate logistic regression analysis demonstrated that Survivin (P = 0.000) and CD44v6 (P = 0.001) expression in surgical margin, T-stage (P = 0.006) and histological grade (P = 0.001) were independent predictive factors for recurrence. The proportional hazards model identified Survivin (P = 0.005) and CD44v6 (P = 0.004) expression in surgical margin, T-stage (P = 0.006) and histological grade (P = 0.001), as independently related to disease-free survival. Using subgroup analysis, we found that the Survivin+/CD44v6+ subgroup has the poorest prognosis, whereas the Survivin-/CD44v6- subgroup has the best prognosis (P = 0.000). CONCLUSIONS: Immunohistochemical assessment of both Survivin and CD44v6 status in negative surgical margin may be a valuable approach for predicting recurrence and survival after curative surgery for laryngeal cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。